Infections caused by Stenotrophomonas maltophilia appear to be increasing in frequency among the immunocompromised population and are challenging to treat. Moreover, resistance to traditional drugs used against these organisms is now becoming more common. Antibiotic options in these circumstances are scarce and new options are needed. We discuss this important topic with experts in the field. Recorded live in Washington DC at ASM Microbe 2022.
- Stenotrophomas maltophilia as an opportunistic pathogen and
- The intrinsic ability of Stenotrophomonas maltophilia to resist common antimicrobials
- Common mechanisms of resistance in Pseudomonas aeruginosa
- Debate on treatment approaches and rationale for these strategies
- Maria Fernanda Mojica PhD Senior Instructor, Case VA Center for Antimicrobial Resistance and Epidemiology. Case Western Reserve University
- Samuel Aitken, PharmD. Adjunct Clinical Professor of Pharmacy, University of Michigan.
Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.